Journal of Clinical Oncology

Article	Citations
The comparison of mutation-based biomarkers for early-stage and advanced-stage non-small cell lung caner.	905
Outcomes after initial refusal of curative treatment in patients with Hodgkin’s lymphoma in British Columbia.	663
Use of neoadjuvant chemotherapy in elderly patients with muscle invasive bladder cancer: A population-based study, 2006 to 2017.	648
Clinical efficacy and safety of proton beam or photon radiation in combination with immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma.	608
Patient factors associated with time to medication receipt of oral anti-cancer drugs.	495
The role of site of metastatic resection (MR) in metastatic colorectal cancer (mCRC) patients (PTS): A mono-institutional cohort study.	462
Baseline neutrophil-to-eosinophil ratio (NER) and its association with clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (CPI).	458
Conversion hepatectomy for hepatocellular carcinoma with inadequate future- remnant- liver after portal vein ligation in combination with apatinib plus camrelizimab: A single-arm prospective pilot stu	411
Racial disparities in second-line (2L) treatment and overall survival among patients (pts) with hormone receptor positive HER2 negative (HR+HER2-) metastatic breast cancer (mBC) treated in routine pra	409
New tropolone derivative to inhibit cell motility in colorectal cancer cells.	395
Phase I study of liposomal irinotecan (LY01610) in patients with advanced esophageal squamous cell carcinoma.	385
Province-wide analysis of patient reported outcomes for stage IV non-small cell lung cancer.	384
Upper respiratory tract SARS-CoV-2 viral shedding in cancer patients.	372
Assessing somatic and germline variants in cancer patients.	369
Analyzing the effects of depression among patients with head and neck cancer.	359
Investigation of immune microenvironment in EGFR mutant NSCLC.	353
Nephrotoxicity in patients with cancer treated with immune checkpoint inhibitors.	329
Efficacy analysis of a remote symptom management platform.	328
Neoadjuvant chemotherapy and disease recurrence after curative-intent surgery in patients with pancreatic adenocarcinoma: A single-center retrospective review.	314
Development of evidence-based clinical pathways for an outpatient oncology acute care clinic.	312
Reducing racial disparities in time to breast cancer diagnosis: Impact of immediate screening mammogram reads during the COVID pandemic.	310
Use of a novel convolutional neural network-based mammographic evaluation to assess response to adjuvant endocrine therapy in women with early-stage breast cancer.	309
Reply to W. Attaallah, A. Jain et al, and P. Mroczkowski et al	295
Final results from ClarIDHy, a global, phase 3, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an isocit	290
Propensity Score Matching for Bias Reduction in Genomic Profiling	284

Early clinical experience with trifluridine/tipiracil for refractory metastatic colorectal cancer: The ROS study.	272
Results of a phase 1 dose-escalation study of AMV564, a novel T-cell engager, alone and in combination with pembrolizumab in patients with relapsed/refractory solid tumors.	261
A novel biosignature identifies DCIS patients with a poor biologic subtype with an unacceptably high rate of local recurrence after breast conserving surgery and radiotherapy.	249
The epidemiological trend of esophageal cancer in Mumbai, India over the past two decades.	237
Alofanib in subsequent therapy for advanced gastric cancer: Final results from the phase Ib clinical trial.	232
The effects of the Covid-19 pandemic on practice patterns and outcomes in patients diagnosed with gynecologic malignancies in the United States.	231
Impact of SARS-COV2 infection on the clinical outcomes in patients with lung cancer compared to all other cancers.	230
Combination polypectomy or excisional biopsy with interventional radiology local tumor destruction versus polypectomy or excisional biopsy for colon cancer: A SEER database analysis.	230
Dacomitinib for patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations: Do mutation patterns matter?	225
Efficacy of eribulin administered in combination with an immune checkpoint inhibitor (ICI) and anlotinib as salvage treatment for patients (pts) with advanced adult soft tissue sarcoma (STS).	224
Lorpucitinib (JNJ-64251330) in patients with familial adenomatous polyposis (FAP): Results from a phase 1b study.	221
Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer.	220
Cancer survival (SURVCANCER BRAZIL): Analysis of 132,621 cases from 19 hospital-based registries in southernmost Brazilian state comparing public and private insurance.	219
Prevalence and patterns of breast white adipose tissue inflammation among American Black women and indigenous Nigerian women with early-stage breast cancer.	218
Long-term follow-up results of ipilimumab and nivolumab for the treatment of mismatch repair deficient locally advanced rectal cancer.	214
Real-world analysis of cardiac, gastrointestinal, and hematologic toxicities between commonly used antiemetics in everyday oncology clinical practice.	213
Clinicopathologic features and outcomes associated with induction regimen intensity among older veterans with myeloma.	211
What differences in outcomes exist in Hispanic patients being treated for lymphoplasmacytic lymphoma and waldenstrom macroglobulinemia?	210
A single-institution analysis of a rare variant of pancreatic neoplasm-osteoclastic giant cell tumor.	208
Regorafenib second-line therapy for surgical recurrent hepatocellular carcinoma: An exploration of continuing regorafenib therapy after tumor progression—A single-center retrospective analysis of 90 c	207
Efficacy of ramucirumab combination chemotherapy as second-line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors a	207
The inclusion of health-related quality of life and other patient-reported outcomes in landmark trials for Food and Drug Administration oncology drug approvals: An analysis of cancer drug approvals be	207
Surgery with adjuvant chemotherapy versus chemoradiation for early-stage large cell neuroendocrine cancer (LCNEC) of the lung: A SEER plus based analysis.	203
Smoking cessation support and knowledge among newly diagnosed individuals at community cancer centers (ECOG-ACRIN trial EAQ171CD).	202
Co-mutation-based subtyping of Chinese patients with gastric cancer.	198
Performance of the OncoUrine test on the predictive capacity of non-muscle-invasive bladder cancer patients who are candidates for repeated transurethral resection.	197
Anticoagulation for portal vein thrombosis in patients with hepatocellular carcinoma: A retrospective observational study.	195
Outcome of immune checkpoint inhibitors in patients with extensive-stage small-cell lung cancer and brain metastases.	195
Adjuvant systemic chemotherapy with or without hepatic arterial infusion of floxuridine in patients following colorectal cancer liver metastases resection (HARVEST): A prospective, randomized controll	194
Prime-boost immunotherapeutic trial in men with biochemical recurrence after definitive local therapy for prostate cancer.	192
Comparing the prognostic implications of spread through airspaces versus lymphovascular invasion in non-small cell lung cancer.	192
Phase II study of telomelysin (OBP-301) in combination with pembrolizumab in gastroesophageal (GEA) adenocarcinoma.	189
Magnetic resonance imaging tumor regression shrinkage patterns during neoadjuvant chemotherapy versus neoadjuvant immunochemotherapy in triple-negative breast cancer (NeoMDSS-TN-SP): A nonrandomized,	189
Evaluating depth of disparities in relation to relative survival rates: Analysis of SEER data.	186
Determinants of widespread metastases and of metastatic tropism in patients with prostate cancer: A genomic analysis of primary and metastatic tumors.	186
Germline mutations in hereditary renal cell carcinoma (RCC) genes among 32,240 patients with all cancer types.	186
Differential tumor gene expression profiling of obese and non-obese patients (pts) with prostatic adenocarcinoma (PC).	185
Prognostic value of total tumor volume with 68Ga DOTATOC PET/CT in predicting response to 177-Lu-DOTATOC treatment in metastatic well-differentiated neuroendocrine tumors (NETs).	183
The smart options of induction therapy for locally advanced betel-nuts related HNSCC in Taiwan.	183
A phase 1 dose-escalation study to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamic activity of cln-619 (Anti-MICA/B antibody) alone and in combination with pembrolizumab in pat	177
Hearing loss related outcomes post-lateral temporal bone resection and other oncologic treatment.	174
Liquid biopsy effectiveness of esophageal cancer-related genes and their correlation in clinical research.	173
The timing of statin initiation on survival outcomes of cancer patients treated with immune checkpoint inhibitors: A retrospective cohort study.	173
A phase II study of regorafenib plus sintilimab as salvage-line treatments in non–MSI-H metastatic colorectal cancer (mCRC).	172
Arterial chemotherapy in advanced hepatocellular carcinoma: An evolutionary trajectory exploration and pooled outcome analysis.	172
Circulating tumor DNA-based molecular residual disease detection for the monitoring of high-grade serous ovarian cancer.	171
High-dose vitamin C to enhance neoadjuvant immune checkpoint therapy in mismatch repair proficient colon cancer: The ALFEO pilot study.	168
The safety and efficacy of cadonilimab in the treatment of advanced and metastatic cervical cancer: A retrospective, real-world study.	167
Sarcopenia vs body mass index (BMI) as a prognostic biomarker in patients with metastatic clear cell renal cell carcinoma (mCCRCC) in the era of first line immune checkpoint inhibitors (ICIs).	167
Systematic high-throughput combination drug screen to enhance poly (ADP-ribose) polymerase (PARP) inhibitor efficacy in ovarian cancer.	162

Epidemiology and clinical trends of testicular cancer and secondary malignant tumors in a north Italian province.	160
Incorporating long non-coding RNA (lncRNA) into genome-wide biomarker screening for prognostic gene signatures of immunotherapy outcomes.	159
Characteristics and outcomes of 795 patients with renal cell cancer following hospitalization for acute myocardial infarction.	159
A master screening study to determine biomarker status and trial eligibility for patients with malignant tumors.	157
Exploratory biomarker analysis of acelERA breast cancer (BC): Phase II study of giredestrant vs. physician’s choice of endocrine therapy (PCET) for previously treated, estrogen receptor-positive, HER2	157
Peaceful acceptance of illness among older adults with cancer.	155
Mechanisms of sensitivity to platinum-based chemotherapy in PD-1 blockade-refractory head and neck cancer.	154
Racial disparities in the outcomes of allogeneic bone marrow transplant: A 5-year nationwide inpatient study.	153
The impact of patient age on palliative care utilization and end-of-life outcomes among patients with metastatic breast cancer.	152
FDA analysis of toxicity profiles of oral TKIs recently approved for non-small cell lung cancer based on receipt of prior immune checkpoint inhibitor therapy.	152
Clinical outcomes of soft tissue sarcoma in the Philippines: A single-center experience.	151
The genomic landscape of adolescent and young adult (AYA) malignancies using DNA and RNA-based next generation sequencing.	151
Treg cells and the response to neoadjuvant chemotherapy combined with immunotherapy in resectable esophageal squamous carcinoma.	151
The five periampullary cancers: Not just different siblings but different families—An international multicenter cohort study.	150
Preclinical evaluation of targeting PRAME with TCR mimic CAR T cells in AML.	150
Predicting the risk of pancreatic cancer in patients with new-onset diabetes based on CT image.	149
Phase II neoadjuvant trial of albumin-bound paclitaxel, trastuzumab and pertuzumab followed by anthracycline based regimens in patients with operable HER2 positive breast cancer (OMC-BC05).	149
Development of CT-based radiomic model to predict 5-year progression-free survival (PFS) in locally advanced head and neck squamous cell carcinoma (LAHNSCC) treated with definitive chemoradiation.	149
Regorafenib in older adults with metastatic colorectal cancer: A multi-center, single arm phase II trial.	148
Efficacy and safety of eribulin as a front-line treatment in patients with advanced breast cancer: The first large scale prospective real-world study in China.	146
Serial ctDNA monitoring to predict response in mCRC patients treated with anlotinib in combination with oxaliplatin and capecitabine (CAPEOX) as the first-line therapy.	145
The prognostic value of patient reported outcomes (PROs) and clinical/demographic variables in the CASPIAN study.	143
Demographics of the tumor formerly known as bronchiolo-alveolar carcinoma.	143
Ex-vivo analysis of programmed cell death on fibrolamellar carcinoma.	142
Real-world, single-center experience on the outcomes of neoadjuvant chemotherapy and trastuzumab alone or in combination with pertuzumab in human epidermal growth factor receptor-2 breast cancer patie	140
Assessment of how differences in efficacy and toxicity change healthcare professionals’ views on presentation of treatment options.	140
Comparison of conventional clinical models and a multigene assay to assess DCIS risk in a prospective single center study.	139
Validation of a novel and rapid reagent free assay to predict outcomes for adjuvant therapy decision making in hormone receptor-positive breast cancer.	138
Clinical and genomic characterization of early-onset pancreatic cancer.	135
Expanding the spectrum of neoplasms harboring EWSR1:CREM fusion as detected by a real-world clinical genomics platform.	135
An ehealth intervention during radical radiotherapy: Patient-Reported Outcome Side effects (PROSE) study—An emerging approach from sub-Saharan Africa.	134
Concurrent EGFR wild-type tongue squamous cell carcinoma and EGFR-mutant lung adenocarcinoma and response to osimertinib.	133
A pragmatic, single-arm clinical trial of a dose-adjustment algorithm for preventing cytopenia-related delays during FOLFOX chemotherapy.	133
Comparison of bevacizumab plus doublet chemotherapy regimens in patients with metastatic or recurrent ovarian cancer.	133
Evaluation of cachexia and outcomes in patients with aggressive B-cell non-Hodgkin lymphoma.	132
A study on oligo-progression after durvalumab plus platinum-etoposide for ES-SCLC.	132
Evaluation of microsatellite instability status, a definitive predictive biomarker for immune checkpoint inhibitors (ICI), in underrepresented minorities (URM) with gastrointestinal (GI) cancers.	130
Enhancing patient clinical streamlining (EPACS) pilot in the breast medicine service at memorial sloan kettering cancer center.	128
Neoadjuvant therapy (NAT) in early breast cancer (EBC): Results from a prospective observational multicenter BRIDE study.	127
Phase I study of the bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 combined with SHR2554, an EZH2 inhibitor, in patients with previously treated advanced lymphoma and solid tumors.	126
TIGIT expression and outcomes in pembrolizumab treated patients with NSCLC.	126
Artificial intelligence (AI) –based machine learning models (ML) for predicting pathological complete response (pCR) in patients with hormone receptor (HoR) –positive/HER2-negative early breast cancer	125
Outcomes of Helicobacter pylori (HP) infection in esophageal cancer (EC): A 5-year nationwide analysis.	125
Racial/ethnic differences in 21-gene recurrence score and survival among estrogen receptor-positive breast cancer patients.	125
Transcatheter arterial chemoembolization using CalliSpheres beads loaded with arsenic trioxide for unresectable large or huge hepatocellular carcinoma: A prospective study.	124
Development and independent validation of a predictive gene expression signature based on RB1, PTEN, and TP53 in patients with metastatic hormone-sensitive metastatic prostate cancer (mHSPC).	124
CDH1-mutated clinically advanced urothelial bladder cancer (UBC): A genomic landscape and real-world clinical outcome study (RWCOS).	123
Factors that determine selection of a cancer treatment location.	123
Ten-year outcomes of hypofractionated (45 Gy in 9 fractions) intensity-modulated radiotherapy for localized prostate cancer.	122
Golidocitinib in treating refractory or relapsed peripheral T-cell lymphoma: Primary analysis of the multinational pivotal study results (JACKPOT8).	122
Digital voice analysis as a measure of frailty and distress: A feasibility study (DIVAN).	122
Exploring the significance of PARP inhibitor therapy after first-line chemotherapy in patients with homologous recombination proficient ovarian cancer: An extracted individual patient data and trial-l	120
A Lasso Cox score consisting of CTLA4+ regulatory T cells (Treg), monocytic myeloid derived suppressor cells (M-MDSC), and CXCR3+ CD8+ T cells: Association with adjuva	120
Survival outcomes and clinicopathological factors analysis of breast cancer patients. A single-institution cohort from 2012 to 2020 in a Mexican population.	119
Penile squamous cell carcinoma (PSCC) with elevated tumor mutational burden (TMB): A genomic landscape study.	119
Adverse events during chimeric antigen receptor T-cell (CAR-T) therapy for hematologic malignancies (HM): Real-world, US patient experience.	118
The association between continuity of Medicaid enrollment and cancer survival in young adults diagnosed with cancer.	118
The effect of ctDNA tumor fraction (TF) on overall survival and concordance between tissue genomics and ctDNA in Lung-MAP.	118
Updated results of the phase 1 I-FLOAT trial: Safety and efficacy of combining genotype-guided irinotecan with 5FU, leucovorin, oxaliplatin and docetaxel (gFOLFOXIRITAX) in advanced upper GI cancers.	118
Spectrum of germline pathogenic variants among patients with cancer in Mexico.	117
Estimating burden of cardiovascular disease among survivors of breast, colorectal, lung, and prostate cancer in the detroit research on cancer survivors (ROCS) cohort.	117
CarePoint assay in the management of bladder cancer: A pilot study.	117
Older patients with early-stage triple-negative breast cancer: The Memorial Sloan Kettering Cancer Center experience.	114
Sociodemographic and clinicopathologic factors of triple negative breast cancer at an academic urban safety-net hospital.	114
Fertility preservation in women with cancer in Brazil: Infertility specialists' perceptions and attitudes.	113
A systematic review with meta-analysis of radiotherapy adverse events in patients with cancer and lupus erythematosus.	113
Comparing digital and glass slide methods for determining the HER2-low and negative categories in breast cancer.	112
Real-world experience of checkpoint inhibitors across India: CRSF 2020-01.	112
Early postoperative outcomes in stent vs stent-less ileal conduits after radical cystectomies.	112
Prevalence of KRAS p.G12C mutation in patients with metastatic non-small cell lung cancer in Argentina.	111
Determinants of resistance to nivolumab (nivo) monotherapy investigated through genomic and transcriptomic analysis of renal cell carcinoma (RCC) tumors from the HCRN GU16-260 study.	111
Rural disparities in telemedicine use among cancer survivors during the COVID-19 pandemic.	110
Open-label study of darolutamide plus androgen-deprivation therapy (ADT) vs ADT in metastatic hormone-sensitive prostate cancer using an external control arm (ARASEC).	109
Mortality and the burden of subsequent malignant neoplasms in survivors of childhood cancer beyond age 50: A report from the Childhood Cancer Survivor Study (CCSS).	109
Effects of concomitant gut-microbiome altering medications on immune checkpoint inhibitors therapy: A retrospective study.	109
The role of micro-CT for intraoperative margin assessment of breast cancer.	109
Population pharmacokinetic and exposure-response safety analyses of mecbotamab vedotin (BA3011) in patients with advanced solid tumors.	108
Hints for reclassification of meningiomas based on the fifth edition of WHO CNS.	107
Representation of age, race and ethnicity in real-world evidence (RWE), randomized clinical trial (RCT), and Surveillance, Epidemiology, and End Results (SEER) cancer patient registry data in advanced	107
A comparison of the Optum Clinicogenomics Solid Tumor Database and the SEER Population-Based Cancer Registry.	107

First report of ELUCIDATOR study: A prospective observational multicenter study on resistance mechanisms in patients with early disease progression during osimertinib.	107
Multi-omics study of the genomic features and clinical characteristics of hepatic sarcomatoid carcinoma located at different sites.	106
Measurable residual disease (MRD) and clonal diversity for multiple myeloma treatment monitoring.	104
Exploring the most appropriate primary endpoint of immune checkpoint inhibitors for previously treated advanced solid cancers.	104
Global circulating free DNA methylation and fragmentome deconvolution in patients with metastatic renal cell carcinoma treated with immunotherapy (GOLDEN).	104
Sequential metastasis-directed therapy (MDT) for oligometastatic prostate cancer (Oligo PCa) assessed by PET-based imaging.	103
Phase II trial of combination pembrolizumab, olaparib, and temozolomide for patients with recurrent glioma.	103
AXL pathway as a target to overcome resistance to PARP inhibitors in high-grade serous ovarian (HGSOC) and triple-negative breast cancer (TNBC) cell lines.	103
Cardiovascular comorbidities and cardiovascular events in patients with metastatic prostate cancer.	102
Integrated clinico-genomic characterization of pancreatic ductal adenocarcinoma in an Asian population.	102
Clinical characteristics, markers of adverse prognosis, and predictors of development of extramedullary multiple myeloma.	102
The identification of blood pattern for gastric cancer from routine blood tests in a territory-wide big clinical database.	101
Navigating how to choose an oncologist as part of the cancer journey.	101
Functional roles of tissue factor and EMMPRIN/CD147 present on bladder urothelial carcinoma-derived extracellular vesicles.	101
A phase II trial of palbociclib combined to letrozole after progression on second-line chemotherapy for women with ER/PR-positive high-grade serous or endometrioid ovarian, fallopian tube, or peritone	101
Characterizing outcomes in severe cytopenias by 3 months in BCMA and CD19 CAR-T cell therapies: A single institution experience.	100
Biologic indicators of donor socioeconomic disadvantage and recipient mortality following allogeneic hematopoietic cell transplantation.	100
Assessing the utility of liquid biopsy for detecting actionable genetic mutations among indigenous Ghanaian women with metastatic breast cancer.	100
HER2-low expression as a prognostic factor in patients treated with CDK4/6 inhibitors: A retrospective analysis.	99
A single institution experience of multimodality radiation therapy for muscle-invasive bladder cancer.	99
Outcome differences by sex in oncology clinical trials.	99
Knowledge and use of different breast cancer screening tools among primary care physicians: A cross-sectional study.	99
Leadership knowledge and beliefs regarding diversity, equity, and inclusion at SWOG Cancer Research Network.	98
A contemporary national population-based analysis of demographics and outcomes of Hispanics with adult T-cell leukemia/lymphoma in the US.	97
Immune-related adverse events after ≥12 months of starting immune checkpoint inhibitors.	97
Phase II study of biweekly TAS-102, irinotecan and bevacizumab in pre-treated metastatic colorectal cancer (TABAsCO).	97
Incidence, landscape and survival outcome of de novo malignancy after double lung transplantation.	97
Five-year overall survival with S-1 plus docetaxel as adjuvant treatment in curatively resected pStage III gastric cancer in JACCRO GC-07.	97
Sequential monitoring of tumor macrophage fusion cells in the circulation of metastatic breast cancer and their prognostic value.	96
Evaluating response to interventions for vasomotor symptoms in patients with breast cancer: A patient-centered approach.	94
Phase I trial of chimeric anti-GPC3 scFv-CD3ε engineered T cells (CT0180) in patients with advanced hepatocellular carcinoma.	94
Elevated cancer risk among individuals with combinations of cancer-related risk factors: A large claims database analysis.	94
Real-world rates of FDA-approved targeted therapy and immunotherapy prescriptions for patients with metastatic colorectal cancer in the VA’s National Precision Oncology Program (NPOP).	94
Effect of pandemic-related reductions in cancer care delivery on different US health systems.	93
Utility of next generation sequencing (NGS) in advanced malignancies in a community hospital in an underserved area: A game changer?	93
Phase 1 study of SGN-BB228, an investigational CD228 x 4-1BB costimulatory antibody anticalin bispecific, in patients with advanced melanoma and other solid tumors (SGNBB228-001).	92
Clinical features of long-term survivors with advanced high-grade serous ovarian cancer.	92
Mortality rate and social disparity trends with tyrosine kinase inhibitory availability in chronic myelogenous leukemia: An analysis in the US from 1999 to 2020.	92
Prognostic value of month 1 bone marrow and PET MRD status in CAR-T therapy for myeloma.	92
Efficacy of paxman scalp cooling system at lower temperatures for prevention of anthracycline associated chemotherapy induced alopecia.	91
Patients characteristics, treatment patterns and clinical outcomes in patients with head and neck squamous cell carcinoma (aHNSCC) receiving immunotherapy in advanced setting: Retrospective cohort ana	91
Genomic and transcriptomic profiling of inflammatory breast cancers and non-inflammatory breast cancers in Asian women.	90
Navigator utilization rates in breast cancer patients by race in a comprehensive cancer center.	90
Statin use for primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD) in breast cancer (BC) patients (pts).	90
CASSIOPE: A prospective noninterventional study of cabozantinib treatment following prior vascular endothelial growth factor (VEGF) -targeted therapy in patients with advanced renal cell carcinoma (aR	90
Ivosidenib off-label use for IDH mutant gliomas: The MD Anderson Cancer Center real life experience.	90
Beyond the binary: Analysis of esophageal cancer hospitalizations in the transgender population, a national inpatient sample study.	89
Does RSClin provide additional information over classic clinico-pathologic scores (PREDICT 2.1, Influence, CTS-5)? A TEAM Pathology substudy.	89
Outcomes according to treatment received for small node-negative HER2+ breast tumors in the Surveillance, Epidemiology, and End Results (SEER) database, 2010-2019.	89
Low-intensity chemotherapy (mini-HCVD) and ponatinib followed by blinatumomab (blina) and ponatinib for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL): A phas	89
Geographical impact on prostate cancer genetic testing eligibility: A preliminary study from an academic cancer center.	88
The first cold atmospheric plasma phase I clinical trial for the treatment of advanced solid tumors: A novel 4th treatment arm for cancer.	88
Exploring HER2-low disease: Does it impact breast cancer survival?	88
Incidence of solid malignancies (SM) among patients with Waldenström macroglobulinemia (WM): Analysis of the SEER database (2000-2019).	88
METASNCore: A new tool for palliative whole brain radiotherapy (WBRT) assessment in the era of targeted therapies.	88
Clinical outcomes of patients who underwent total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC): A single center experience.	87
Using telehealth to conduct serious illness conversations (SIC) for patients with metastatic lung cancer during the COVID-19 pandemic.	86
Comparison of real-world outcomes over time in a large population-based cohort of patients with metastatic breast cancer.	86
Overall survival outcomes in older patients with metastatic breast cancer: A National Cancer Database analysis.	85
waveLINE-006: A phase 2 study of the safety and efficacy of zilovertamab vedotin as monotherapy or in combination in patients (pts) with aggressive and indolent B-cell malignancies.	85
Construction of a prognostic hierarchical model for patients with HER2 positive breast cancer with brain metastases.	84
Efficacy and safety study of osimertinib in advanced non-small cell lung cancer (NSCLC) with EGFR mutation.	84
Impact of adjuvant immunotherapy in resected stage II/III/IV melanoma: A single center experience.	84
Lack of organization to access cancer treatment in southeast Brazil: Urgent need to change.	84
Prospective evaluation of cell-free DNA fragmentation profiles for lung cancer detection.	83
Influence of chromatin remodeling molecule ARID1A on metastatic heterogeneity in triple negative breast cancer: Binding of YAP.	83
Increasing the study of novel anticancer therapies in adolescents: Facilitating adolescent inclusion in adult research.	82
Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: An AGEO European Cohort.	82
Imbalance in treatment discontinuation without progression between experimental and control arms among randomized trials in advanced breast cancer.	82
Urine-based epigenetic profiling for detection of clear cell renal cell carcinoma: A prospective study.	82
Cascade genetic testing (CGT) female first-degree relatives (FDR) of men with germline BRCA2 mutations (gBRCA2mut) and prostate cancer (PCa): A cost-effectiveness analysis.	81
Immunotherapy combined with rh-endostatin improved clinical outcomes over ICIs plus chemotherapy for second-line treatment of advanced NSCLC.	80
Representativeness of patients with lung cancer in an integrated health care delivery system.	80
Longitudinal associations between peripheral neuropathy and neurocognitive decline in long-term survivors of pediatric cancer treated without central nervous system (CNS) directed therapy.	79
Real world clinical outcomes of patients with HER2 positive metastatic breast cancer with central nervous system involvement treated with modern regimens.	79
Sun exposure and associated risks: Insight from an international survey with a focus on the organ transplant recipient population.	78
Real-world use of tisagenlecleucel in children and young adults with relapsed or refractory B-cell lymphomas.	78
Oncology financial advocacy services guidelines: Results of a Delphi study.	78
The 2022 NCI Community Oncology Research Program (NCORP) Landscape Committee Assessment: Methods and participating practice group characteristics.	78
Disparate impact of healthcare access restrictions due to COVID-19 pandemic on breast cancer diagnosis and treatment.	78
Impact of overfixation on actionable biomarkers and checkpoint inhibitor (CKI) targets with immunohistochemistry (IHC) in a patient population with non-small cell lung cancer (NSCLC).	78
Outcomes and safety of subsequent treatments after immune- and anti-VEGF therapy in patients with metastatic clear-cell renal cell carcinoma: Outcomes from a tertiary referral hospital.	78
Addressing the clinical trial selection process to improve representation by African American patients with breast cancer in cancer clinical trials.	77
Efficacy analysis of CDK4/6 inhibitors (CDKi) + endocrine therapy (ET) treatment in hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer (aBC): Biomarker analysis including chemo	77
Trastuzumab-induced cardiotoxicity in breast cancer patients: A meta-analysis and review of the literature (2012-2022).	77
Comparison of diversity across real-world evidence, randomized clinical trial, and Surveillance, Epidemiology, and End Results (SEER) data in patients with metastatic breast cancer.	77
Comprehensive characterization of androgen receptor expression in breast cancer.	77
Faith-based communities’ preferred interventions to improve the participation of black/African-American persons in medical research and clinical trials: A focus group study.	77
Ceruminous adenocarcinoma: A National Cancer Database study of demographic characteristics.	76
Determinants of permanent liver limited disease (pLLD) in metastatic colorectal cancer (mCRC).	76
Are we missing the beat in cancer end-of-life care: Prevalence and end-of-life monitoring of implantable cardioverter defibrillators in a population-based sample of older adults diagnosed with breast,	76
Uptake of MRI in patients without a personal history of breast cancer (PHBC) classified as “high risk”.	76
Breast cancer brain metastases: The graded prognostic assessment index (GPA) in a real-world low- and middle-income (LMIC) population.	75
Lenalidomide-based monotherapy versus augmented therapy for maintenance in standard risk multiple myeloma patients with no complete response post autologous hematopoietic cell transplantation.	75
Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US): NRG-GI008.	75